Annuncio • Jun 04
Coloplast Announces FDA Approval of Titan Prime Inflatable Penile Prosthesis Coloplast announced FDA approval of Titan Prime, an inflatable penile prosthesis (IPP) that represents the company’s next-generation device and will be available in the U.S. in late 2026. Around 30 million men in the US experience ongoing difficulty in getting or keeping an erection firm enough for sexual activity. As an alternative to medication, some benefit from long-term treatment options such as an inflatable penile prosthesis, which is delivered through a single outpatient procedure. Inflatable Penile Prosthesis Titan Prime IPP is designed to emulate the appearance and performance of a natural erection, supporting device performance for patients, surgeons, and partners. Built with proprietary Bioflex – a polymer engineered for greater strength and durability than silicone – Titan Prime IPP delivers greater material strength than leading silicone competitors and withstands higher pressures to reinforce reliability. Titan Prime IPP preserves the rigidity and girth surgeons trust from Titan IPP today, while providing improved flaccid flexibility for comfort and concealability. The result is consistent, predictable outcomes across diverse male anatomies. Titan Prime is now FDA-approved and will be available through a phased launch to urologists and health care systems in the United States beginning in late 2026. Titan Prime IPP is approved for use in the United States by the FDA. Coloplast is pursuing regulatory approvals in other countries, where the product is not yet available. Annuncio • May 13
Coloplast A/S Announces Interim Dividend for the First Half Ended March 31, 2026 Coloplast A/S announced that it will pay a interim dividend of DKK 5.00 per share, for a total dividend pay-out of DKK 1,127 million for the first half ended March 31, 2026. Annuncio • Mar 07
Coloplast A/S Announces President Changes Coloplast A/S's board of directors announced the appointment of Gavin Wood as the new President and Chief Executive Officer (CEO) of the Coloplast Group, effective May 1, 2026. Gavin Wood will take over from interim CEO Lars Rasmussen, who has been in the role since May 5, 2025. Gavin Wood has spent two decades in different leadership roles in Johnson & Johnson, most recently as Company Group Chairman of Johnson & Johnson MedTech EMEA, a multi-billion-dollar business with more than 7,000 employees working across three business units: Surgery, Orthopedics, and Cardiovascular & Specialty Solutions. Earlier in his career, he led the Ethicon Wound Closure & Healing team as Worldwide President, and prior to that, he served as Executive Vice President, Commercial, at Mölnlycke. Gavin Wood currently serves as Vice Chair of the MedTech Europe trade association. He holds a Bachelor of Arts degree in Law from Carleton University, Canada and an MBA from Queen’s University, Canada. He is Canadian by birth, currently lives in Switzerland, and he will be relocating to Denmark. Lars Rasmussen will continue to lead Coloplast as interim CEO until the end of April. Annuncio • Mar 06
Coloplast A/S Announces CEO Changes Coloplast A/S's board of directors announced the appointment of Gavin Wood as the new President and Chief Executive Officer (CEO) of the Coloplast Group, effective May 1, 2026. Gavin Wood will take over from interim CEO Lars Rasmussen, who has been in the role since May 5, 2025. Gavin Wood has spent two decades in different leadership roles in Johnson & Johnson, most recently as Company Group Chairman of Johnson & Johnson MedTech EMEA, a multi-billion-dollar business with more than 7,000 employees working across three business units: Surgery, Orthopedics, and Cardiovascular & Specialty Solutions. Earlier in his career, he led the Ethicon Wound Closure & Healing team as Worldwide President, and prior to that, he served as Executive Vice President, Commercial, at Mölnlycke. Gavin Wood currently serves as Vice Chair of the MedTech Europe trade association. He holds a Bachelor of Arts degree in Law from Carleton University, Canada and an MBA from Queen’s University, Canada. He is Canadian by birth, currently lives in Switzerland, and he will be relocating to Denmark. Lars Rasmussen will continue to lead Coloplast as interim CEO until the end of April. Annuncio • Feb 06
Coloplast A/S Provides Earnings Guidance for the Fiscal Year 2025-2026 Coloplast A/S provided earnings guidance for the fiscal year 2025-2026. For the year, the company expects around 7% EBIT growth in constant currencies. Annuncio • Dec 19
Coloplast A/S Announces Executive Changes Coloplast A/S announced changes to its Executive Leadership Team, affecting the Interventional Urology business and the global People & Culture function. Executive Vice President of People & Culture, Dorthe Rønnau, has decided to leave Coloplast to pursue the next chapter in her career. She has spent close to three decades in different roles across the Coloplast Group, including Global Operations, Atos, and People & Culture, and in her role in the Executive Leadership Team. An external search is currently on-going to identify a new leader of the global People & Culture function. Dorthe Rønnau will have her last day at Coloplast at the end of February 2026, where Mads Mikkelsen, Vice President, People & Culture, Chronic Care Commercial, will take over the interim leadership of the global People & Culture organisation until a permanent successor has been identified. After more than a decade in Coloplast and more than three decades in the global life science industry, Tommy Johns, Executive Vice President of Interventional Urology, will retire early next year. Tommy Johns has been instrumental in identifying his successor, ensuring a period of overlap between Tommy and his successor to ensure a thorough handover prior to Tommy’s final day with Coloplast early next year. Kevin Hardage will step into the role of Executive Vice President of Interventional Urology. He joins Coloplast on February 9, 2026. Kevin brings extensive experience from the global MedTech industry, including senior leadership experience from Teleflex in the urology space. Annuncio • Oct 09
Coloplast A/S Announces Interim CEO Lars Rasmussen Will Step Down from the Board At the Upcoming Annual General Meeting on December 4, 2025 Coloplast interim CEO Lars Rasmussen has informed the Coloplast Board of Directors that he will not stand for re-election as board member at the upcoming annual general meeting on December 4, 2025. Lars Rasmussen will, as announced earlier this year, continue in the role as interim CEO until a new CEO of Coloplast is in place. Jette Nygaard-Andersen will continue in the role of interim Chair and, together with the Board of Directors, lead Coloplast in the coming period, as the company enters into its next strategic period of long-term, sustainable growth and value creation. Jette Nygaard-Andersen has been a member of the Board since December 2015 and interim Chair since May 5, 2025. The Board of Directors are unanimously supportive of the announced changes. The search for Coloplast’s new CEO is progressing according to plan, and an announcement will follow once a decision has been made. Annuncio • Oct 01
Coloplast A/S, Annual General Meeting, Dec 03, 2026 Coloplast A/S, Annual General Meeting, Dec 03, 2026. Annuncio • Dec 05
An undisclosed buyer acquired Coloplast's Skin Care business from Coloplast A/S (CPSE:COLO B). An undisclosed buyer acquired Coloplast's Skin Care business from Coloplast A/S (CPSE:COLO B) on December 3, 2024.
For the period ending September 30, 2024, Coloplast's Skin Care business reported total revenue of DKK 400 million.
An undisclosed buyer completed the acquisition of Coloplast's Skin Care business from Coloplast A/S (CPSE:COLO B) on December 3, 2024. Annuncio • Nov 15
Coloplast A/S Announces Kerecis Includes on List of Covered Products for Diabetic Foot Ulcers in Final LCD Policy Coloplast A/S announced on 14 November 2024, the U.S. Centers for Medicare & Medicaid Services (CMS) issued a final Local Coverage Determination (LCD) policy regarding skin substitute grafts/cellular and tissue-based products for the treatment of Diabetic Foot Ulcers (DFUs) and venous leg ulcers (VLUs) in the Medicare population. The final LCD policy confirms the introduction of a technical qualification and a clinical efficacy qualification, proposed in a draft LCD policy2 earlier this year. The final decision also introduces two separate lists for covered products for DFUs and covered products for VLUs. In addition, the application limit has been expanded from 4 to 8 and the duration of treatment has been increased from 12 to 16 weeks in the final policy. The implementation date of the final policy is set to 12 February 2025. Based on the final evaluation, Kerecis is included on the final list of covered products for DFUs, however, Kerecis has not been included on the covered list for VLUs. Sales related to VLUs in the out-patient setting currently represent a low-single digit portion of the total Kerecis’ sales. Kerecis has an ongoing clinical study on VLUs and will attempt to get coverage for VLUs as soon as the study is completed. Annuncio • Nov 06
Coloplast A/S to Report Nine Months, 2025 Results on Aug 19, 2025 Coloplast A/S announced that they will report nine months, 2025 results on Aug 19, 2025 Annuncio • Sep 27
Coloplast A/S, Annual General Meeting, Dec 04, 2025 Coloplast A/S, Annual General Meeting, Dec 04, 2025. Annuncio • Aug 20
Coloplast A/S Re-Affirms Earnings Guidance for the Fiscal Year 2023/24 Coloplast A/S re-affirmed earnings guidance for the fiscal year 2023/24. For the period, the company expects organic revenue growth to be around 8%. Reported growth in DKK is expected to be 10% to 11%. Annuncio • Feb 01
Coloplast A/SLaunches Biatain® Silicone Fit for Pressure Injury Prevention and Wound Management in the US Coloplast A/S aims to expand its position within advanced wound care by introducing a new silicone foam that will benefit both healthcare professionals and patients. Changing demographics and an aging population are leading to a higher demand for healthcare services, putting significant strain on healthcare systems. In the US, chronic wounds are reported to affect 10.5 million patients annually1, while 2.5 million patients develop a pressure injury in acute care facilities each year2. Therefore, it is critical for healthcare providers to choose products that simplify their workflows and deliver the best possible care for their patients. Annuncio • Dec 08
Coloplast A/S Approves the Distribution of Year-End Dividend Coloplast A/S approved the distribution of year-end dividend of DKK 16 per share of nominally DKK 1, at the AGM held on December 7, 2023. Annuncio • Sep 02
Coloplast A/S (CPSE:COLO B) completed the acquisition of Kerecis, LLC Coloplast A/S (CPSE:COLO B) signed an agreement to acquire Kerecis, LLC for $1.3 billion on July 7, 2023. The total enterprise value for 100% ownership of Kerecis amounts to up to $1.3 billion, consisting of $1.2 billion upfront cash payment and an earnout potential of maximum $100 million dependent on financial performance in FY 2023/24. The transaction is expected to be financed through an equity capital raise of around DKK 9 billion ($1.3 billion). Following the expected acquisition, Kerecis will operate as a stand-alone business unit under its own identity and brand. Kerecis reported a revenue of DKK 510 million ($74.36 million) in FY 2021/22.
Closing of the transaction is subject to customary regulatory approvals and an acceptance threshold of at least 90%, and is anticipated in Q4 2022/23. Kerecis’ Board of Directors has recommended to the company’s minority shareholders to sell their shares in Kerecis to Coloplast. 77% of Kerecis’ shareholders have committed to sell their shares to Coloplast. The acquisition is expected to be margin dilutive short-term for Coloplast. The transaction is expected to be increasingly EPS accretive from FY 2026/27. Coloplast’s financial guidance for FY 2022/23 excluding transaction related costs is unchanged. Special items for FY 2022/23 are expected to increase by DKK 50 million due to transaction related costs (advisory fees).
Ulrik Falk, Morten Sløk and Niklas Mortensen of FIH Partners acted as financial advisors to Coloplast A/S. Jeppe Buskov, Morten Kofmann and Oliver Machholdt of Kromann Reumert acted as Lead Legal Advisor and PWC acted as financial advisor to Coloplast. Danske Bank will act as Sole Global Coordinator in connection with the equity capital raise and Joint Bookrunner together with Nordea. J.P. Morgan acted as exclusive financial advisor to Kerecis. Logos Legal Services advised Kerecis on Icelandic law matters. Mark P. Holloway, Michael C. Labriola, Ross Davies, Sarah Lane, Stephen R. Heifetz, Michael S. Casey, Anne E. Seymour, Beau Buffier, Kimberley Biagioli, Andrew Poling, Martin Luff, Matt Staples and Paul S. Gadiock of Wilson Sonsini Goodrich & Rosati, P.C. acted as legal advisor to Kerecis.
Coloplast A/S (CPSE:COLO B) completed the acquisition of Kerecis, LLC on August 31, 2023. Annuncio • Aug 17
Coloplast A/S Provides Earnings Guidance for the Fiscal Year 2022/2023 Coloplast A/S provided earnings guidance for the fiscal year 2022/2023. Organic revenue growth continues to be expected around 8%. Reported revenue growth is still expected at 8% to 9%. Annuncio • Jul 08
Coloplast A/S (CPSE:COLO B) signed an agreement to acquire Kerecis, LLC for $1.3 billion. Coloplast A/S (CPSE:COLO B) signed an agreement to acquire Kerecis, LLC for $1.3 billion on July 7, 2023. The total enterprise value for 100% ownership of Kerecis amounts to up to $1.3 billion, consisting of $1.2 billion upfront cash payment and an earnout potential of maximum $100 million dependent on financial performance in FY 2023/24. The transaction is expected to be financed through an equity capital raise of around DKK 9 billion ($1.3 billion). Following the expected acquisition, Kerecis will operate as a stand-alone business unit under its own identity and brand. Kerecis reported a revenue of DKK 510 million ($74.36 million) in FY 2021/22. Closing of the transaction is subject to customary regulatory approvals and an acceptance threshold of at least 90%, and is anticipated in Q4 2022/23. Kerecis’ Board of Directors has recommended to the company’s minority shareholders to sell their shares in Kerecis to Coloplast. 77% of Kerecis’ shareholders have committed to sell their shares to Coloplast. The acquisition is expected to be margin dilutive short-term for Coloplast. The transaction is expected to be increasingly EPS accretive from FY 2026/27. Coloplast’s financial guidance for FY 2022/23 excluding transaction related costs is unchanged. Special items for FY 2022/23 are expected to increase by DKK 50 million due to transaction related costs (advisory fees).FIH Partners acted as transaction advisors, Kromann Reumert acted as Lead Legal Advisors, and PWC acted as financial advisors to Coloplast. Danske Bank will act as Sole Global Coordinator in connection with the equity capital raise and Joint Bookrunner together with Nordea. J.P. Morgan acted as exclusive financial advisor to Kerecis. Annuncio • May 11
Coloplast A/S Provides Earnings Guidance for the Fiscal 2023 Coloplast A/S provided earnings guidance for the full fiscal year 2022/2023. For the period, the company reports organic revenue growth is now expected around 8% in constant exchange rates, from 7-8% previously. Reported growth in DKK is now expected to be 8-9%, from previously 9-10%, due to negative impact from currencies. Consequently, the reported EBIT margin is now expected in the 28-29% range, from previously 28-30%. Annuncio • Feb 04
Coloplast Launches Male Catheter Designed to Reduce the Risk of Urinary Tract Infections Coloplast launches male catheter designed to reduce the risk of urinary tract infections. The new intermittent catheter Luja addresses important risk factors for urinary tract infections, a significant burden for people using intermittent catheters as well as healthcare systems as a whole. Urinary tract infections represent a significant challenge for people who use intermittent catheters to empty their bladder. This includes people living with spinal cord injury, multiple sclerosis, or spina bifida. On average, intermittent catheter users have 2-3 urinary tract infections per year1-3, which can lead to serious health complications4, have a significant impact on quality of life2, and result in hospitalisation5-9, thereby putting pressure on local healthcare systems. Coloplast is now launching Luja, the first and only male catheter featuring 80+ micro-holes, aiming to address important UTI risk factors1 linked to intermittent catheterisation. Flow stops and blockage of the catheter eyelets during emptying increase the risk of leaving residual urine behind in the bladder. Residual urine increases the risk of bacteria growth and is a well-known UTI risk factor. The launch of Luja begins this month, February, in Denmark and Finland, and the product is expected to be available across Coloplast’s key markets over the next 12 months. Coloplast is currently conducting two pivotal clinical studies to document and demonstrate the benefits of Luja. The results are expected to be publicly available within the next few months. In 2021/22, the global market for continence care products was worth an estimated 15-16 billion DKK with an underlying annual market growth of 5-6%. Coloplast is the global market leader in continence care, and the company continues to outgrow the market and take market share. The launch of Luja is expected to contribute to Coloplast’s growth trajectory and help solidify the company’s global market leader position. Luja has close to no flow stops and complete bladder emptying is defined as <10 mL (CP353, NCT05485922). Annuncio • Feb 03
Coloplast A/S Provides Earnings Guidance for the Fiscal Year 2022/23 Coloplast A/S provided earnings guidance for the Fiscal Year 2022/23. For the period, Organic revenue growth is expected at 7% to 8% in constant exchange rates. Reported EBIT margin before special items is still expected at 28% to 30%, impacted by increasing input costs, especially raw materials and electricity in Hungary, partly offset by leverage, efficiency gains and prudent management of operating costs.